(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **02940232AA** 

Total Pages in this Submission

## TO THE COMMISSIONER FOR PATENTS

Mail Stop Patent Application P.O. Box 1450 Alexandria, VA 22313-1450

Transmitted here	ewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent applicat	ion for an
	DE CANNABINOID AGONISTS AND ANTAGONISTS	s. PT0
and invented by:		
Billy R. Martin	n, Raj K. Razdan, Roger G. Pertwee	1958
If a CONTINUA	TION APPLICATION, check appropriate box and supply the requisite information:	
Continuati	ion Divisional Continuation-in-part (CIP) of prior application No.:	
Which is a:  Continuati Which is a:	ion Divisional Continuation-in-part (CIP) of prior application No.:	
☐ Continuat	ion Divisional Continuation-in-part (CIP) of prior application No.:	
Enclosed are:	Application Elements	
1. 🔲 Filin	ng fee as calculated and transmitted as described below	
2. 🗵 Spe	ecification having 3I pages and including the following:	
a. 🛚	Descriptive Title of the Invention	
b. 🗆	Cross References to Related Applications (if applicable)	
c. 🗵	Statement Regarding Federally-sponsored Research/Development (if applicable)	
d. 🗆	Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix	
e. 🗵	Background of the Invention	-
f. 🛚	Brief Summary of the Invention	
g. 🗵	Brief Description of the Drawings (if filed)	
h. 🗵	Detailed Description	
i. 🗵	Claim(s) as Classified Below	
j. 🛚	Abstract of the Disclosure	

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 02940232AA

Total Pages in this Submission

### **Application Elements (Continued)** ☑ Drawing(s) (when necessary as prescribed by 35 USC 113) a. Formal **Number of Sheets** b. 🛛 Informal **Number of Sheets** Oath or Declaration a. Newly executed (original or copy) Unexecuted Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only) b. 🔲 With Power of Attorney ☐ Without Power of Attorney DELETION OF INVENTOR(S) d. 🔲 Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b). ☐ Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. ☐ CD ROM or CD-R in duplicate, large table or Computer Program (Appendix) ☐ Application Data Sheet (See 37 CFR 1.76) 7. □ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included) a. Computer Readable Form (CFR) b. Specification Sequence Listing on: i. D CD-ROM or CD-R (2 copies); or ii. 🗌 Paper c. Statement(s) Verifying Identical Paper and Computer Readable Copy **Accompanying Application Parts** ☐ Assignment Papers (cover sheet & document(s)) ☐ 37 CFR 3.73(B) Statement (when there is an assignee) ☐ English Translation Document (if applicable) Copies of IDS Citations 12. ☐ Information Disclosure Statement/PTO-1449 □ Preliminary Amendment 13. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed) Certificate of Mailing

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **02940232AA** 

Total Pages in this Submission

Accompanying Application Parts (Continued)		
17.	X	Applicant claims small entity status. See 37 CFR 1.27.
		Optional) Small Entity Statement(s) - Specify Number of Statements Submitted:
18.		Additional Enclosures (please identify below):
		Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
19.		Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
		Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **02940232AA** 

Total Pages in this Submission

### **Fee Calculation and Transmittal**

#### **CLAIMS AS FILED** For #Filed #Allowed #Extra Rate Fee **Total Claims** 16 - 20 = 0 \$9.00 \$0.00 \$336.00 Indep. Claims 11 - 3 = 8 \$42.00 \$0.00 Multiple Dependent Claims (check if applicable) \$375.00 **BASIC FEE** \$0.00 OTHER FEE (specify purpose) **TOTAL FILING FEE** \$711.00 ☐ A check in the amount of to cover the filing fee is enclosed. ☐ The Director is hereby authorized to charge and credit Deposit Account No. as described below. ☐ Charge the amount of as filing fee. □ Credit any overpayment. ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b). June 24, 2003 Dated:

cc:

PATENT TRADEMARK OFFICE

Ruth Tyler-Cross Reg No. 45,922

703-787-9400

Reston, Virginia 20190

Whitham, Curtis & Christofferson, P.C.

11491 Sunset Hills Road, Suite 340